

allereye™



The only non-invasive, rapid,
Point-of-Care (POC) test for
Allergic Conjunctivitis (AC)

 **bluejay**
DIAGNOSTICS

THE CONJUNCTIVITIS DIAGNOSIS


Every year, millions of people visit their doctors seeking relief from conjunctivitis, which always involves eye redness or swelling, and can be caused by a virus, bacterium or allergens. However, it can sometimes be difficult to make a firm diagnosis because symptoms are often the same no matter the cause.

Proper differential diagnosis is an essential prerequisite for appropriate treatment. A co-existence of indications may occur driving the need for specific POC diagnostic tests.

- A bacterial infection can occur independently, or following an allergic reaction from a secondary source such as eye rubbing.
- The co-existence of allergic and viral infections is extremely rare.
- The co-existence of allergic and bacterial infections is also extremely rare.
- Allergic reactions tend to occur simultaneously in both eyes.

Allergic conjunctivitis is the most frequent cause of non-infectious conjunctivitis and it often goes untreated. Currently, an Allergic Conjunctivitis (AC) diagnosis is confirmed by patient history, invasive eye swab or skin test, serum test or even a negative viral test leading to inefficiencies and increased costs. The *Allereye™ Tear Total IgE Test* confirms the presence of IgE antibodies in tears. It also offers the ability to now make a specific POC diagnosis, which can prevent unnecessary dry-eye treatment and unnecessary antibiotic regimen mandated by the Affordable Care Act.

Allergic Conjunctivitis is one of the most common disorders of the ocular surface, and it affects approximately 30% of the population, both in the United States and worldwide.¹ Allereye provides clinics the opportunity to offer new testing and gain new efficiencies in patient care—all while reducing costs. Having specific IgE POC test results available immediately allows for quicker, more effective diagnosis and treatment. Further, by making the diagnosis in house, revenue is not lost as is often the case when testing is sent out. Allereye's cost-effective, POC format also makes it an option for some private pay patients.



30%

of the population is
affected by AC¹

1. Gomes PJ. Trends in prevalence and treatment of ocular allergy. *Curr Opin Allergy Clin Immunol.* 2014 Oct;14(5):451-6.


THE *ALLEREYE*TM TEAR TOTAL IGE TEST

Allereye is an FDA Cleared POC device that offers healthcare providers a cost effective, reliable, easy to use solution to aid in the diagnosis of Allergic Conjunctivitis (AC). It's also more comfortable and convenient for patients.

The reagent-ready test strip format is easy to use and integrate into most clinics. Simply collect a small tear sample directly onto the test strip, place it in the *Allereye* Development Solution and ten minutes later the results are ready (Figure 1).

Each test strip also contains a control line to indicate it is performing correctly. The limited amount of materials also means less risk of handling errors, requires very little space to perform and produces minimal waste.


FIGURE 1. Illustrative procedure



The *Allereye Tear Total IgE Test* confirms the presence of IgE antibodies in tears. It also offers the ability to now make a specific POC diagnosis, which can prevent unnecessary dry-eye treatment and unnecessary antibiotic regimen.

- Receive an objective analysis in just 10 minutes.
- Collect only a tear drop from the inferior conjunctival fornix (Figure 2). The test strip will indicate when sufficient sample has been collected.
- *Allereye*'s sensitivity is more than ninety-two percent and its specificity more than ninety-eight percent compared to the gold-standard serum IgE testing..
- Patients can be diagnosed quickly and easily minimizing time missed from work, school and life.
- *Allereye* is reimbursable by most major insurance carriers. Eye-swab tests, serum tests and skin tests cost up to ten times more than *Allereye*.

FIGURE 2. Inferior Conjunctival Fornix





Bluejay Diagnostics, Inc., develops, manufactures and markets non-invasive Point-of-Care (POC) tests. The company, which is headquartered in Acton, Massachusetts, was founded with the mission of providing patients and providers access to affordable and timely healthcare in markets with unmet needs. In 2018 Bluejay will launch its flagship product, the *Allereye™ Tear Total IgE Test*, an FDA-Cleared POC test to aid in the diagnosis of allergic conjunctivitis.

Bluejay Diagnostics, Inc.
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
Toll-Free: 1 844 327 7078
International: 1 978 631 4884
Fax: 1 978 263 1801
BluejayDX.com

Allereye is a trademark of Bluejay Diagnostics, Inc. in the United States and other countries worldwide.

© 2018 Bluejay Diagnostics, Inc. All rights reserved.
D#0001r02